SymBio Pharmaceuticals Limited
San-Ei Building, 5-23-7 Shimbashi, Minato-ku, Tokyo 105-0004, Japan
Tel: +81-3-5472-1125 Fax: +81-3-5472-3054 http://www.symbiosis.co.jp/

March 25, 2008

SymBio Pharmaceuticals Limited.
Fuminori Yoshida
Representative Director, President and Chief Executive Officer

The U.S. Food and Drug Administration (FDA) has approved New Drug Application for TREANDA® (bendamustine HCl)

We will inform of the release article that the U.S. Food and Drug Administration (FDA) has approved TREANDA® (bendamustine hydrochloride) for Injection for the treatment of patients with chronic lymphocytic leukemia. Please refer to the attached paper excerpt article.

It is our pleasure to announce that this approval by FDA, to become a driving force for SymBio Pharmaceuticals in the acceleration of its research and business development in Japan and other Asian countries. We also see this event serving as a firm guidance for SymBio Pharmaceuticals in its target to complete the final clinical trial for the drug in the first quarter of 2008.

Contact:
SymBio Pharmaceuticals Limited.
Osamu Ogawa
Board Director, Senior Corporate Officer, Research & Development,
Tel: +081(0)3 5472 1123
E-mail: Please send your inquiry through “INQUIRY” in our homepage
URL:http://www.symbiosis.co.jp

News Release

Cephalon Receives FDA Approval for TREANDA® (bendamustine HDl), a Novel Chemotherapy for Chronic Lymphocytic Leukemia. First New Agent for CLL Patients Approved by the U.S. Food and Drug Administration (FDA) Since 2001

FRAZER, Pa.-March 20, 2008

Cephalon, Inc. (Nasdaq: CEPH) today announced that the U.S. Food and Drug Administration (FDA) has approved TREANDA® (bendamustine hydrochloride) for Injection for the treatment of patients with chronic lymphocytic leukemia (CLL), a slowly progressing blood and bone marrow disease. The American Cancer Society estimates that more than 15,000 new cases of this rare disease will be diagnosed in the United States this year. The TREANDA® application as a CLL treatment received priority review from the FDA and was approved within six months of the September 2007 submission. Cephalon anticipates that TREANDA® will be available to physicians and patients as a CLL treatment in the United States in April 2008.

"TREANDA® is an important new treatment for patients with chronic lymphocytic leukemia, and this first-cycle approval by FDA represents a significant milestone in the growth of our oncology business," said Dr. Lesley Russell, Executive Vice President, Worldwide Medical and Regulatory Operations. "With a strong pipeline of near- and longer-term opportunities, Cephalon Oncology is poised to deliver therapies that target both hematologic cancers and solid tumors for patients in need of new options."

Dr. Bruce Cheson, Professor of Medicine at Georgetown University Hospital, Washington, D.C., stated, "Patients with chronic lymphocytic leukemia can often live normal lives for many years because of treatments that control the disease over the long-term. TREANDA® is an effective new option that offers a delay in disease progression, an important goal for patients with chronic lymphocytic leukemia."

In a randomized, international, multicenter, open-label pivotal study of 301 treatment-naive patients with CLL, those who received TREANDA® had better clinical outcomes compared to patients treated with chlorambucil, an FDA-approved chemotherapy for patients with CLL. Specifically, TREANDA® patients had a significantly higher overall response (59 percent of

patients responded to TREANDA® and 26 percent of patients responded to chlorambucil; $p < 0.0001$). Patients who received TREANDA® also had a higher complete response rate than those treated with chlorambucil (8 percent vs. <1 percent), which means that after treatment with TREANDA®, some patients had no signs of disease in their blood.

Importantly, TREANDA® patients also had a significantly longer progression-free survival (18 months vs. 6 months; Hazard Ratio = 0.27; $p < 0.0001$), meaning the disease did not get worse for a significant period of time. The response to TREANDA® lasted longer (duration of response) than in patients who received chlorambucil (19 months vs. 7 months). The most common adverse events in the trial were myelosuppression, fever, nausea, and vomiting.
TREANDA® has been granted orphan drug status by the FDA for the treatment of CLL. The orphan drug designation will provide marketing exclusivity in this indication until March 2015.

[Company Profile]
About SymBio Pharmaceuticals Limited
SymBio Pharmaceuticals' focus is on oncology/hematology and autoimmune disease therapies. Established in March 2005 by Fuminori Yoshida, who previously served as both Corporate Vice President of Amgen Inc. and president of Amgen Japan, SymBio Pharmaceuticals' underlying corporate philosophy is "delivering hope to patients in need," and the company aims to address unmet medical needs of patients in Japan by cultivating a mutually beneficial or symbiotic relationship among physicians, scientists, regulatory agencies, and investors.
SymBio Pharmaceuticals core philosophy is that profitability and socially responsibility as a pharmaceutical enterprise can go hand in hand, and need not be mutually exclusive.